Britain recommends not using AstraZeneca Covid vaccine for under-30s

Britain should not give Oxford University/AstraZeneca’s vaccine to under 30s where possible, Britain’s Joint Committee on Vaccination and Immunisation (JCVI) said on Wednesday, due to a very rare side effect of blood clots in the brain. The Sun newspaper and Sky News reported they would be given Pfizer or Moderna instead.

Wei Shen Lim, COVID-19 Chair for JCVI, said that based on the available data and evidence, the committee has advised that it is preferable for adults aged under 30 with no underlying conditions to be offered an alternative to the vaccine where available.

“We are not advising a stop to any vaccination for any individual in any age group. We are advising a preference for one vaccine over another vaccine for a particular age group, really out of the utmost caution, rather than because we have any serious safety concerns,” he said at a briefing.

He said people should continue to have a second dose of the shot if they had received a first dose.

It came after Britain’s MHRA medicine regulator identified a possible side-effect from the COVID-19 vaccine developed by Oxford University and involving rare brain blood clotting.

Chief executive June Raine said that the benefits of the shot outweighed the risks for the vast majority.

Meanwhile, the EU’s drug regulator says it has found a possible link between the AstraZeneca vaccine and a rare clotting disorder but said that the benefits of the shot still outweigh risks.

In a statement released Wednesday, the European Medicines Agency placed no new restrictions on using the vaccine in people 18 and over.

Earlier this week, a senior official from the European Medicines Agency said there was a causal link between the AstraZeneca vaccine and the rare clots that have been seen in dozens of people worldwide, among the tens of millions who have received at least one dose of the shot.

Marco Cavaleri, head of health threats and vaccine strategy at the Amsterdam-based agency, said in comments to Rome’s Il Messaggero newspaper on Tuesday that it is becoming more and more difficult to affirm that there isn’t a cause-and-effect relationship between AstraZeneca vaccines and the very rare cases of blood clots associated with a low level of platelets.

But Cavaleri acknowledged the agency hadn’t yet figured out how exactly the vaccine might be causing these rare side effects. The agency said its evaluation has not yet reached a conclusion and the review is currently ongoing.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Leave a Reply

Your email address will not be published. Required fields are marked *